MarketCap
Facebook
X
TelegramProgenity, Inc. Revenue | PROG
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Progenity, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 74.3 M | 144 M | 128 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 144 M | 74.3 M | 115 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akari Therapeutics, Plc
AKTX
|
368 K | $ 7.95 | 2.57 % | $ 535 B |  Britain |
 |
Mersana Therapeutics
MRSN
|
40.5 M | - | - | $ 3.56 B |  USA |
 |
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | USA |
 |
Genmab A/S
GMAB
|
10.1 B | $ 53.62 | 1.67 % | $ 3.47 B |  Danmark |
 |
Timber Pharmaceuticals
TMBR
|
83.2 K | - | - | $ 717 K | USA |
 |
Ionis Pharmaceuticals
IONS
|
203 M | $ 39.67 | 2.24 % | $ 6.35 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
264 M | $ 8.1 | 4.59 % | $ 2.89 M | USA |
 |
Immuron Limited
IMRN
|
7.29 M | $ 0.82 | -3.68 % | $ 189 M |  Australia |
 |
G1 Therapeutics
GTHX
|
82.5 M | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
223 M | - | - | $ 621 M | Britain |
 |
MediWound Ltd.
MDWD
|
21.8 M | $ 14.18 | 6.38 % | $ 386 M |  Israel |
|
Cerevel Therapeutics Holdings
CERE
|
2.72 M | - | - | $ 7.29 B | USA |
 |
Nektar Therapeutics
NKTR
|
55.2 M | $ 37.25 | 3.04 % | $ 628 M | USA |
 |
Immunome
IMNM
|
6.94 M | $ 18.71 | 4.5 % | $ 1.63 B | USA |
 |
Kala Pharmaceuticals
KALA
|
3.89 M | $ 0.16 | 2.1 % | $ 1.3 M | USA |
 |
Theravance Biopharma
TBPH
|
45.9 M | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
IMV
IMV
|
188 K | - | - | $ 13.1 M |  Canada |
 |
Karuna Therapeutics
KRTX
|
654 K | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
212 K | - | - | $ 756 M | USA |
 |
LogicBio Therapeutics
LOGC
|
5.41 M | - | - | $ 229 M | USA |
 |
Fusion Pharmaceuticals
FUSN
|
2.07 M | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
16.3 M | - | 0.42 % | $ 213 M | USA |
 |
Harpoon Therapeutics
HARP
|
31.9 M | - | - | $ 763 M | USA |
 |
HOOKIPA Pharma
HOOK
|
43.9 M | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
12.2 M | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
47.8 M | - | - | $ 109 M | USA |
 |
Otonomy
OTIC
|
125 K | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
3.09 M | - | 17.91 % | $ 11.1 M | USA |
 |
Seagen
SGEN
|
1.96 B | - | - | $ 42.2 B | USA |
 |
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
2.32 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | USA |
 |
Zosano Pharma Corporation
ZSAN
|
785 K | - | 7.23 % | $ 2.72 M | USA |
 |
Oncternal Therapeutics
ONCT
|
785 K | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
37 K | - | - | $ 591 K |  Irlanda |
 |
Spectrum Pharmaceuticals
SPPI
|
10.1 M | - | - | $ 189 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Alpine Immune Sciences
ALPN
|
58.9 M | - | - | $ 2.17 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
32.6 M | - | - | $ 401 M | USA |
 |
ImmunoGen
IMGN
|
109 M | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
310 K | - | -8.77 % | $ 12.4 M | Israel |
 |
Histogen
HSTO
|
3.77 M | - | 31.6 % | $ 2.12 M | USA |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |